One important risk factor for the development of asthma is allergen sensitization. Recent increasing evidence suggests a prominent role of mast cells in asthma pathophysiology. Since Palmitoylethanolamide (PEA), an endogenous lipid mediator chemically related to – and co-released with- the endocannabinoid anandamide, behaves as a local autacoid down-regulator of mast cell activation and inflammation, we explored the possible contribution of PEA in allergic sensitization, by using ovalbumin (OVA) as sensitizing agent in the mouse. PEA levels were dramatically reduced in the bronchi of OVA-treated animals. This effect was coupled to a significant up-regulation of CB2 and GPR55 receptors, two of the proposed molecular PEA targets, in bronchi harvested from allergen-sensitized mice. PEA supplementation (10 mg/kg, 15 min before each allergen exposure) prevented OVA-induced bronchial hyperreactivity, but it did not affect IgE plasma increase. On the other hand, PEA abrogated allergen-induced cell recruitment as well as pulmonary inflammation. Evaluation of pulmonary sections evidenced a significant inhibitory action of PEA on pulmonary mast cell recruitment and degranulation, an effect coupled to a reduction of leukotriene C4 production. These findings demonstrate that allergen sensitization negatively affects PEA bronchial levels and suggest that its supplementation has the potential to prevent the development of asthma-like features.

Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse / Roviezzo, Fiorentina; Rossi, Antonietta; Caiazzo, Elisabetta; Pierangelo, Orlando; Riemma, MARIA ANTONIETTA; Iacono, Valentina M.; Guarino, Andrea; Ialenti, Armando; Cicala, Carla; Alessio, Peritore; Capasso, Raffaele; Vincenzo Di Marzo, ; Izzo, ANGELO ANTONIO. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 8:articolo 857(2017), pp. 1-11. [10.3389/fphar.2017.00857]

Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse

Roviezzo, Fiorentina
Co-primo
;
Rossi, Antonietta
Co-primo
;
Caiazzo, Elisabetta;Riemma, MARIA ANTONIETTA;Andrea, Guarino;Ialenti, Armando;Cicala, Carla;Capasso, Raffaele;Angelo, A. IZZO
Ultimo
2017

Abstract

One important risk factor for the development of asthma is allergen sensitization. Recent increasing evidence suggests a prominent role of mast cells in asthma pathophysiology. Since Palmitoylethanolamide (PEA), an endogenous lipid mediator chemically related to – and co-released with- the endocannabinoid anandamide, behaves as a local autacoid down-regulator of mast cell activation and inflammation, we explored the possible contribution of PEA in allergic sensitization, by using ovalbumin (OVA) as sensitizing agent in the mouse. PEA levels were dramatically reduced in the bronchi of OVA-treated animals. This effect was coupled to a significant up-regulation of CB2 and GPR55 receptors, two of the proposed molecular PEA targets, in bronchi harvested from allergen-sensitized mice. PEA supplementation (10 mg/kg, 15 min before each allergen exposure) prevented OVA-induced bronchial hyperreactivity, but it did not affect IgE plasma increase. On the other hand, PEA abrogated allergen-induced cell recruitment as well as pulmonary inflammation. Evaluation of pulmonary sections evidenced a significant inhibitory action of PEA on pulmonary mast cell recruitment and degranulation, an effect coupled to a reduction of leukotriene C4 production. These findings demonstrate that allergen sensitization negatively affects PEA bronchial levels and suggest that its supplementation has the potential to prevent the development of asthma-like features.
2017
Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse / Roviezzo, Fiorentina; Rossi, Antonietta; Caiazzo, Elisabetta; Pierangelo, Orlando; Riemma, MARIA ANTONIETTA; Iacono, Valentina M.; Guarino, Andrea; Ialenti, Armando; Cicala, Carla; Alessio, Peritore; Capasso, Raffaele; Vincenzo Di Marzo, ; Izzo, ANGELO ANTONIO. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 8:articolo 857(2017), pp. 1-11. [10.3389/fphar.2017.00857]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/694656
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 33
social impact